A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants with Unresectable Locally Advanced or Metastatic Solid Tumors

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed locally advanced or metastatic solid tumor (including stomach, colorectal, lung, and head and neck cancers) that has progressed after standard treatment or has no standard treatment options remaining - adequate bone marrow, kidney, and liver function - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- significant uncontrolled medical conditions, including serious heart disease, lung disease, active infection, or recent major surgery active autoimmune disease requiring treatment or known HIV, hepatitis B, or hepatitis C infection - active or unstable brain metastases or other untreated central nervous system disease - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Interventions:
Drug: TAK-505
Conditions:
Cancer, Cancer, Cancer
Keywords:
Clinics and Surgery Center (CSC)

More Information

Description: The purpose of this study is to evaluate how TAK-505 works in people with certain advanced solid tumors, including stomach, colorectal, lung, and head and neck cancers. The study will test TAK-505 at different dose levels to understand how it is tolerated, how it behaves in the body, and to help determine the dose that provides the best balance of effect and side effects for future studies.
Study Contact: Nicholas Zorko - zorko004@umn.edu
Principal Investigator: Nicholas Zorko
Phase: PHASE1
IRB Number: STUDY00027296